Cosmos Health Inc. (COSM)
| Market Cap | 9.36M |
| Revenue (ttm) | 69.49M |
| Net Income (ttm) | -21.13M |
| Shares Out | 54.34M |
| EPS (ttm) | -0.59 |
| PE Ratio | n/a |
| Forward PE | 2.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,275,890 |
| Open | 0.181 |
| Previous Close | 0.185 |
| Day's Range | 0.163 - 0.205 |
| 52-Week Range | 0.163 - 1.320 |
| Beta | 4.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 21, 2026 |
About COSM
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), N... [Read more]
Financial Performance
In 2025, Cosmos Health's revenue was $65.27 million, an increase of 19.93% compared to the previous year's $54.43 million. Losses were -$19.14 million, -14.45% less than in 2024.
Financial StatementsNews
Cosmos Health signs distribution agreement with IMC
Cosmos Health (COSM) announced a distribution agreement with International Medical Company to expand its presence in the State of Qatar for its proprietary Sky Premium Life line of nutraceuticals and…
Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar's Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units
Cosmos Health signs distribution agreement with IMC, owner of Qatar's largest pharmacy chain. Secures purchase order of 31,000 Sky Premium Life units.
Cosmos Health’s Cana advances international patent application
Cosmos Health (COSM) announced that its wholly owned subsidiary, Cana Laboratories, has advanced international patent application WO2025108566A1 into the European regional phase and the national phase...
Cosmos Health Advances International Patent Application for Its Proprietary Hydrogel Weight Management Platform Across the U.S., Europe, Australia, and Canada
Building on Its Recent Acquisition of the CCX0722 Intellectual Property, Cosmos Health Owns the Technology Outright and Is Now Pursuing Patent Protection Across Four Major Healthcare Markets Within th...
Cosmos Health's C-Sept PRO Gains Strong Traction Across Leading Greek Public and Private Hospital Groups, With Annualized Sales Poised to Exceed $1.3 Million at Approximately 72% Gross Margin
CHICAGO, June 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided an update ...
Cosmos Health to deploy AI-powered call center
Cosmos Health (COSM) announced that it has signed an agreement to deploy an artificial intelligence-powered call center to support customer communications, including order intake and routine support f...
Cosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating Efficiency
CHICAGO, June 23, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it h...
Cosmos Health builds contract manufacturing orderbook to over 25M units
Cosmos Health (COSM) provided a consolidated summary of the contract manufacturing orderbook secured through its wholly owned subsidiary, Cana Laboratories. Cana has secured a cumulative orderbook of ...
Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit
CHICAGO, June 22, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided a consolid...
CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity
CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its ...
Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States
CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced its entry...
Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products
CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that, thr...
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
CHICAGO, June 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided an update ...
Cosmos Health’s Cana wins contract manufacturing orders totaling 253,657 units
Cosmos Health (COSM) announced that its wholly-owned subsidiary, Cana Laboratories, has received new contract manufacturing orders from Nassington and Verisfield for a combined 253,657 units across a ...
Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines
CHICAGO, June 12, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its...
Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit
Strong sales momentum: across the UK and Greece, the brands' first two markets. Over $1.5 million in sales: C-Scrub and C-Sept have generated over $1.5 million in combined annualized sales across the ...
Cosmos Health to acquire Doc Pharma, terms undisclosed
Cosmos Health (COSM) announced that it has entered into a non-binding letter of intent to acquire 100% of Doc Pharma, a fully licensed GMP pharmaceutical manufacturer. The company expects the…
Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit. Immediately accr...
Cosmos Health secures 180-day extension to regain Nasdaq compliance
Cosmos Health (COSM) has been granted an additional 180-day period to regain compliance with the Nasdaq minimum bid price requirement. On June 10, the Company received written notification from the…
Cosmos Health unit signs three-year contract with Verisfield
Cosmos Health (COSM) announced that its wholly-owned subsidiary, Cana Laboratories, has secured a three-year contract manufacturing agreement with Verisfield S.A., a specialty pharmaceutical company f...
Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its...
Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway
Key Highlights Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2. Record operational momentum: CosmoFarm wholesale distribution and GMP-certi...
Cosmos Health unit wins contract manufacturing agreement with Provident Pharma
Cosmos Health (COSM) announced that its wholly-owned subsidiary, Cana Laboratories, has inaugurated a new, state-of-the-art capsule production line and secured an additional contract manufacturing agr...
Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN
CHICAGO, June 09, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its...
Cosmos subsidiary acquires ownership of patent application from Cloudpharm
Cosmos Health (COSM) announced that its wholly owned subsidiary, Cana Laboratories, has acquired ownership of international patent application from Cloudpharm, and expands its nanotechnology investmen...